Navigation Links
Solos Endoscopy, Inc. Successfully Completes Level I FDA Inspection
Date:3/2/2012

BOSTON, March 2, 2012 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company has successfully completed, during the month of February, its Food and Drug Administration (FDA) Level I Baseline Inspection. The Company received a NAI (No Action Indicated) for the inspection.

It is standard for the FDA to periodically perform unannounced inspections for medical device manufacturers and the successful inspection by the FDA validates the Company's quality system and its strict adherence to that system. The site approval accorded by the FDA will enable the Company to continue to supply its high quality endoscopic instrument lines to hospitals, clinics, healthcare centers, medical centers and surgery centers across the United States.

"Compliance to current regulatory standards and guidelines is critical for Solos and its customers. This approval is a true testimony to the high standards of quality, regulatory compliance and operating standards at our company," stated Bob Segersten, President of Solos Endoscopy, Inc.

Solos Endoscopy currently has its endoscopic instruments in over 60 hospitals, clinics, healthcare centers, medical centers and surgery centers across the United States. Solos has focused its R & D efforts into the design and development of new modifications to its endoscopic instrument lines to accommodate the continual advances in laparoscopic surgical procedures. The significant advances over the past several years have led to a number of advantages to the patient with laparoscopic surgery versus an open procedure (laparotomy). These advantages include reduced pain due to smaller incisions and hemorrhaging, and shorter recovery time.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the Pink OTC Markets (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

CONTACT:
AMANDA SEGERSTEN,
RSEGERSTEN@SOLOSENDOSCOPY.COM


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy, Inc. Announces Retirement of 150 Million Common Shares
2. Solos Endoscopy, Inc. is Primed for Growth in 2012
3. Solos Endoscopy, Inc. Reports Significant Sales From Its MammoView® Instrument Line
4. Solos Endoscopy Finishes the 3rd Quarter With a Net Profit
5. Solos Endoscopy Poised for Tremendous Growth in Multi-Billion Dollar Endoscopic Market
6. Solos Endoscopy Goes Google
7. Solos Endoscopy Finishes the 3rd Quarter Strong
8. Solos Endoscopy to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US Hospitals
9. Solos Endoscopy to Market its MammoView® Breast Endoscopy Components to US Hospitals
10. Solos Endoscopy Reports 32% Increase in Breast Endoscopy Sales
11. Solos Endoscopy to Reduce Debt by Over $620,000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology scientists, Dr ... biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm ... on the ASX. Noxopharm is a clinic-ready company with ... 1 clinical study later this year. ... problems facing cancer patients - the ability of cancers to become ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... The ... OSHA Training Institute Education Center headquartered in Northern California, has issued an important ... heat at their worksites. Employers with workers exposed to high temperatures should ...
(Date:6/27/2016)... Aliso Viejo, California (PRWEB) , ... June 27, 2016 , ... ... that are fully customizable inside of Final Cut Pro X," said Christina Austin - ... with another unique style. Final Cut Pro X users can now reveal ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... for mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... solutions to the network of the Tennessee Counseling Association, adding exclusive benefits and ...
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... technology to revolutionize the emergency ambulance transport experience for the millions of people ... how Uber has disrupted the taxi industry through the use of technology. Now, ...
Breaking Medicine News(10 mins):